AILERON THERAPEUTICS INC 4
4 · AILERON THERAPEUTICS INC · Filed Jul 5, 2017
Insider Transaction Report
Form 4
CVF, LLC
10% Owner
Transactions
- Purchase
Common Stock
2017-07-05$15.00/sh+180,000$2,700,000→ 716,180 total - Conversion
Series E-3 Preferred Stock
2017-07-05−4,411,765→ 0 total→ Common Stock (443,973 underlying) - Conversion
Series F Preferred Stock
2017-07-05−916,262→ 0 total→ Common Stock (92,207 underlying) - Conversion
Common Stock
2017-07-05+536,180→ 536,180 total
Footnotes (2)
- [F1]The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]Richard H. Robb, manager of CVF, LLC, exercises voting and investment power with respect to shares held by CVF, LLC. Mr. Robb disclaims beneficial ownership of all shares held by CVF, LLC, except to the extent of his pecuniary interest therein.